Please forgive me if this has already been posted, I searched and couldn't find it.
Munschauer is leaving neurological institute
What I see in the article below is definitely NOT coincidental. Dr. Frederick Munschauer III is also chairman of the University at Buffalo Department of Neurology. The article says he is leaving the Jacobs Neurological Institute, not the University at Buffalo Department of Neurology.
Why is he leaving? TO BECOME VICE PRESIDENT OF U.S. MEDICAL AFFAIRS FOR BIOGEN IDEC, a pharmaceutical company best known for its multiple sclerosis therapies.
So, this guy is to become the vice president of U.S. medical affairs for Biogen, while also serving as chairman of the University at Buffalo Department of Neurology.
This article was written Jan. 27, 2010
Conflict of interest? I’d say a MAJOR one.
Biogen is getting scared, and trying to protect its interests. I don’t know how the results will come out, but if they are not favorable, we’ll know why.
The chief of the Jacobs Neurological Institute in Buffalo is leaving to become vice president of U.S. medical affairs for Biogen Idec, a pharmaceutical company best known for its multiple sclerosis therapies.
Dr. Frederick Munschauer III, an authority on multiple sclerosis and such vascular diseases as stroke, also is chairman of the University at Buffalo Department of Neurology.
There is no cure for MS, but in the last 26 years, a handful of medications have come to market to treat the exacerbations and slow the course of the disease. Research by Munschauer and the late Dr. Lawrence D. Jacobs, a Buffalo neurologist, played a key role in the development of Biogen's Avonex, the drug most widely prescribed to treat relapsing MS.
Munschauer, whose family's roots in Buffalo date back to 1823, said the Cambridge, Mass.-based Biogen has new drugs in development that can slow the progression of MS, as well as one that may reverse the disability the disease causes.
"It was not an easy decision. But I have an opportunity to influence the next generation of drugs for MS, and that's very exciting," he said.
Neurologist Dr. Robert Sawyer has been named interim chief of the institute while a search is conducted to find a replacement.
Biogen, of course, is the manufacturer of Avonex and Tysabri.[/b]